LAMP patent
We Have Obtained a European Patent for Our LAMP Technology
We are pleased to announce that the European Patent Office has granted MultiplexDX International a European patent for our innovative LAMP technology (Loop-mediated Isothermal Amplification).
This technology became the foundation of our IVD-certified LAMP gargle tests, which we successfully deployed during the pandemic. Thanks to this innovation, we were also able to develop mobile testing units that played a key role in mass testing – whether at cultural and sports events, in schools, across various cities in Slovakia, or at border crossings during the outbreak of the war in Ukraine.
The entire process of development,validation, and practical implementation of our tests was also published in the international scientific journal Biology Communications.
This European patent demonstrates that MultiplexDX is developing cutting-edge and flexible diagnostic solutions that can be quickly adapted for the detection of other viruses with epidemic or pandemic potential.
Our vision is to bring innovations that help protect people’s health in Slovakia and around the world.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
